Plain-English translation of NCT07746583 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Psoriasis research guide →This study is observing how well Guselkumab works for people with moderate to severe psoriasis who are switching from a different medication called Ustekinumab. Researchers will collect information from your regular doctor's visits and medical records to see how effective this medication is and how safe it is in real-world clinical practice. No study medication will be provided—you'll be receiving the treatment your doctor has already decided is right for you.
Doctors sometimes need to switch patients to a different psoriasis medication when their current treatment isn't working well enough or causes side effects. This study wants to understand how well this medication works in everyday practice when patients make that switch, so doctors can make better treatment decisions for future patients.
You likely qualify if…
You likely don't qualify if…
This is not an interventional study—you won't be asked to do anything extra beyond your regular psoriasis care. Your doctor will prescribe and monitor the new medication as usual, and researchers will simply collect information from your medical records and routine visits to see how well the treatment is working. The study will track your progress over time using data your doctor already gathers during normal appointments.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
Hungary
Sponsor
Janssen-Cilag Kft.
Enrollment target
~100 participants
Started
September 2026
Primary completion
January 2029
Age range
18 Years and older
Last updated on clinicaltrials.gov in September 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Study Contact
Janssen-Cilag Kft.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.